BACKGROUND: Adolescents and young adults (AYAs) ages 15 to 39 years with cancer continue to experience disparate survival outcomes compared with their younger and older counterparts. This may be caused in part by differential access to specialized cancer centers (SCCs), because treatment at SCCs has been associated with improved overall survival. The authors examined social and clinical factors associated with AYA use of SCCs (defined as Children's Oncology Group-designated or National Cancer Institutedesignated centers). METHODS: A retrospective, population-based analysis was performed on all hospital admissions of AYA oncology patients in California during 1991 through 2014 (n 5 127,250) using the Office of Statewide Health Planning and Development database. Multivariable logistic regression analyses examined the contribution of social and clinical factors on always receiving care from an SCC (vs sometimes or never). Results are presented as adjusted odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Over the past 20 years, the percentage of patients always receiving inpatient care at an SCC increased over time (from 27% in 1991 to 43% in 2014). In multivariable regression analyses, AYA patients were less likely to always receive care from an SCC if they had public insurance (OR, 0.64; 95% CI, 0.62-0.66), were uninsured (OR, 0.51; 95% CI, 0.46-0.56), were Hispanic (OR, 0.88; 95% CI, 0.85-0.91), lived > 5 miles from an SCC, or had a diagnosis other than leukemia and central nervous system tumors. CONCLUSIONS: Receiving care at an SCC was influenced by insurance, race/ethnicity, geography, and tumor type. Identifying the barriers associated with decreased SCC use is an important first step toward improving outcomes in AYA oncology patients.
INTRODUCTION
The incidence of cancer in adolescents and young adults (AYAs) is increasing and is the leading cause of nonaccidental deaths in this age group (ages 15-39 years). 1 AYA patients with cancer have worse survival than younger patients with rhabdomyosarcoma, Ewing sarcoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, and eye and orbit cancer. 2 In addition, cancer mortality has declined in all age groups except for those between ages 15 and 29 years in the last 3 decades. [3] [4] [5] The exact cause for lack of improvement in AYA oncology survival outcomes is unknown. One factor may be limited access to specialized centers of cancer care. 1 When patients with cancer are treated at specialized cancer centers (SCCs), such as Children's Oncology Group (COG)-designated [6] [7] [8] [9] or National Cancer Institute (NCI)-designated cancer centers, [10] [11] [12] [13] [14] [15] they have improved overall survival compared with patients who are treated at non-SCCs. Treatment at these centers may lead to improvement in quality of life and survival because of state-of-the-art diagnostics, expertise, treatment protocols, 16 and clinical trial enrollement. 11, 17, 18 Because no standard quality measure exists for cancer care for AYA patients, NCI Comprehensive Cancer Center designation has been suggested as a surrogate marker. 13 Population-based research in AYA oncology has traditionally used cancer registry data that capture the initial diagnosing or treating facility. 13, 14, [19] [20] [21] However, to more fully understand the nexus of a patient's care, it is important to consider all of the different hospitals where patients receive their cancer care. To fill this gap in the research, we used the Office of Statewide Health Planning and Development (OSHPD) database, which captures every hospitalization in California except for military and prison hospitals. By using this database, we sought to examine a comprehensive sample of all AYA patients (ages 15-39 years) with cancer to elucidate the influences of clinical and sociodemographic factors on their use of SCCs. In addition, this study evaluated a 23-year time-period to determine whether there have been any changes in the use of SCCs by this age group over time. Determining which patients in this vulnerable population are not treated at SCCs and the associated factors is an important first step toward determining where and to whom interventions should be targeted to increase appropriate use of these centers, decrease barriers to access to these centers, and improve outcomes for this patient population.
MATERIALS AND METHODS

Study Design
We used the private OSHPD database to conduct a retrospective, population-based analysis of AYA oncology hospital admissions in California from 1991 to 2014. The major outcome of interest was hospitalization at an SCC.
Participants
The study population included AYAs ages 15 to 39 years who were hospitalized in acute care hospitals in California from 1991 to 2014 with an oncologic diagnosis. Record linkage numbers, which were proprietary to the OSHPD database, were used to link multiple admissions to the same patients. Twelve percent of the admissions in the OSHPD database were unable to be linked to a particular patient because of a missing record linkage number.
Study Variables
The private OSHPD database contains detailed information on all inpatient discharges for all California hospitals (404 acute care hospitals), excluding federal facilities and prison hospitals. It includes the principal diagnosis and up to 24 secondary diagnoses based on the International Classification of Diseases, Ninth Revision-Clinical Modification (ICD-9-CM). Oncology diagnosis codes were designated into the following categories using the Surveillance, Epidemiology, and End Results Program AYA Site Recode Categories 22 and Clinical Classification Software 23 : leukemia, lymphoma, central nervous system (CNS) tumors, bone tumors, respiratory tumors, gastrointestinal tumors, and other solid tumors. Skin cancers were not treated as a separate category, because they are usually treated on an outpatient basis.
The OSHPD database provides de-identified data, including age, race/ethnicity, sex, zip code of residence, payer source (public, private, uninsured, other health insurance), length of hospital stay, and location of hospitalization. Each individual's admissions are under 1 unique identifier, even if there are multiple admissions.
SCCs were defined as designated COG member institutions or NCI-designated cancer centers. COG designation indicates interdisciplinary pediatric cancer care and enrollment of patients into COG clinical trials. 24 NCI designation as a cancer center requires that institutions are dedicated to research and to developing more effective ways to prevent, detect, and treat cancer. 25 There are 28 SCCs in California (24 COG-designated centers, 4 NCI-designated centers, and 4 COG-designated and NCI-designated centers). We defined SCC care in the following way: always was for patients who always received care at an SCC, sometimes was for patients who received care at both SCCs and community centers, and never was for patients who never received care at an SCC throughout the study period. The sometimes group comprised only 14% of the total cohort. Zip-code household-level income was broken into 3 categories based on the Federal Poverty Level (FPL): < 2 3 FPL, 2 to 4 3 FPL and >4 3 FPL. Claritas data (Claritas I population facts database, 2004) were used to derive median household income determined by the 2004 FPL designation at the zip-code level. Distance was calculated as the midpoint between a patient's zipcode and the closest SCC.
The second hospitalization was used to determine health insurance status, zip-code level household income, and distance to SCC, because these are potentially subject to change throughout the patient's course of treatment (10.6% of patients changed zip codes and 7.6% changed type of health insurance coverage during the study period). For example, patients may not have any insurance at diagnosis but may soon acquire emergency insurance or other coverage. If there was only 1 admission, then information from that admission was used.
Statistical Analysis
For initial descriptive analyses, the Student t test was used to compare demographic and clinical characteristics between AYA oncology patients who always, sometimes, and never received care from an SCC. Univariate logistic regression analyses were performed to analyze the association of the following a priori independent variables with always (vs sometimes or never) receiving care at an SCC: AYA age group, sex, health insurance status, race/ethnicity, zip-code level household income, distance to SCC, and tumor type (leukemia, lymphoma, etc). Factors that were identified as significantly associated (P < .01) in univariate analyses (age, sex, insurance, race/ethnicity, zipcode FPL, distance to SCC, diagnosis, and year of care) were included in the multivariate logistic regression model. A sensitivity analysis was performed that included patients with a first admission at a non-SCC and all subsequent visits at an SCC in the always at an SCC group. In addition, as a sensitivity analysis, logistic regression was used to evaluate the association of demographic and clinical characteristics with never (vs sometimes or always) receiving care from an SCC to ensure that the sometimes group was not influencing the findings. We also evaluated whether the classification of SCCs among oncology patients ages 15 to 25 years influenced the factors associated with care at these centers. In this sensitivity analysis, SCCs were defined as care received at COG-designated centers (for those ages 15-25 years) and at NCIdesignated centers (for those ages 15-39 years).
Results are presented as odds ratios (ORs) and 95% confidence intervals (CIs). P values < .01 were deemed statistically significant. All analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC). This study was approved by the Stanford University Institutional Review Board and the State of California Committee for Protection of Human Subjects.
RESULTS
The analysis included 127,250 individuals with a combined total of 376,862 hospital admissions over a 23-year period.
SCC Use Over Time
In aggregate, over the entire 23-year period, among hospitalized AYA oncology patients, 57% never, 14% sometimes, and 29% always received care at an SCC (Fig. 1) . Between 1991 and 2014, the percentage of patients who always received care at an SCC increased (from 27% in 1991 to 43% in 2014). Adolescent patients (ages 15-18 years) were more likely to have received care at an SCC, and the percentage of young patients who received care at an SCC increased over time (Fig. 2) . The percentage of patients ages 15 to 18 years who received 
Demographics
The majority of patients were aged 32 years (58%) (Table 1). Adolescents (ages 15-18 years) comprised the largest proportion of patients who always (60%) versus never (22%) received care from an SCC (P < .001). Older AYA oncology patients (32 years of age) made up a larger proportion of patients never (62%) versus always (26%) having received care from an SCC (P < .001). The majority of patients had private insurance (62%); however, the vast majority of uninsured patients never received care at an SCC (72%).
Patients with leukemia, CNS tumors, and bone tumors were disproportionately more likely to have always received care from an SCC ( Table 1) . Although the majority of patients lived within 10 miles of an SCC (56%), the farther patients lived from an SCC, the more likely they were to never be admitted to an SCC.
Factors Associated With Always Receiving Care at an SCC
Because the vast majority of patients always received care either from a non-SCC (57%) or from an SCC (29%) (Fig. 1) , we evaluated the factors associated with always receiving care from an SCC ( Table 2 ). In addition, compared with nonHispanic whites, Native-Americans (OR, 1.43; 95% CI, 1.13-1.82; reference, non-Hispanic whites) were more likely to always receive care at an SCC, whereas Hispanics (OR, 0.88; 95% CI, 0.85-0.91) were less likely to always receive care at an SCC.
AYA oncology patients with public insurance (OR, 0.64; 95% CI, 0.62-0.66, reference private) or no health insurance (OR, 0.51; 95% CI, 0.46-0.56) were less likely to always receive care from SCCs compared with those who had with private insurance ( Table 2 ). The greater the distance an AYA oncology patient resided from an SCC, the less likely they were to always receive care from an SCC. AYA oncology patients with CNS tumors were more likely to always receive care from an SCC than AYA patients with any other diagnosis. The results were similar when patients who had only a first discharge at a Original Article
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Cancer non-SCC and their remaining discharges at an SCC were included in the group that always received care at an SCC (data not shown). In addition, the logistic regression evaluating the characteristics of never (vs sometimes or always) receiving inpatient care at an SCC demonstrated similar results, ensuring that the sometimes group was not a significant contributor to the findings (data not shown).
The analysis of predictors of always receiving care at a COG-designated center (for ages 15-25 years) and an NCI-designated center (for ages 15-39 years) versus sometimes or never receiving such care demonstrated results that were similar to those from the original analysis (data not shown).
DISCUSSION
The findings from our study revealed an overall increase in SCC use over time, but the trend was not experienced equally, because some subsets of AYA oncology patients were less likely to always be admitted to an SCC. Those who had disparate access to specialized cancer care were older, had public or no health insurance, were of Hispanic race/ethnicity, and resided farther from an SCC. Our study demonstrates that younger patients (ages 15-21 years) are more likely to be discharged from an SCC, and this has increased substantially over time. In concordance with our study, Wolfson et al demonstrated that a larger proportion of patients aged 15 to 21 years received care at cancer centers compared with older patients. 15 The increase in SCC use among patients ages 15 to 21 years may be explained in part by the increased awareness by physicians of the improved outcomes of some AYA cancers at pediatric cancer centers [7] [8] [9] or on pediatric protocols 16, 26, 27 and the overall special needs of AYA oncology patients. 1 In addition, the diagnosing physician of these younger patients may be more likely to be either a pediatrician, who may be more likely to refer to a COG-designated center (or SCC), or an adult physician, who feels less comfortable treating younger patients with cancer.
Declines in SCC use was independently associated with increasing age and may result from older patients (aged > 27 years) being more likely than their younger counterparts to have a job and family obligations that prevent them from traveling to an SCC. 28 In a study of patients with CNS tumors in Los Angeles County, insurance status, low socioeconomic status, and distance to the center were identified as barriers to specialty cancer care in the group ages 22 to 39 years. 15 Outside the AYA age group, age also influences the use of SCCs. For example, during our study period, 92.9% of pediatric oncology patients (aged 14 years) and 22.3% of older adult oncology patients (aged 40 years) received treatment at an SCC. However, regardless of age, increasing distance between residence and the nearest SCC is also a barrier to always receiving care from an SCC. This may be explained by patient preference 28 to have procedures done close to home, although traveling to a higher quality center might improve their outcome, or it could be reflective of local physician referral networks. In addition, declines in SCC use with increasing age may be a reflection of referral patterns in which a patient may be seen by a local oncologist who views them as an adult and does not refer them elsewhere, 29 is not aware of where clinical trials are available, or is not aware of the potential benefit of receiving care at an SCC. 13, 14, 30 We observed that Hispanics were less likely than non-Hispanic whites to always receive care from an SCC. This disparity in SCC use by Hispanic patients has been previously described. [31] [32] [33] Furthermore, language barriers, cultural differences, immigrant status, difficulty with transportation, and long waiting times have been identified as barriers to accessing general health care by parents of Hispanic children, 34, 35 factors that may contribute to decreased use of SCCs by Hispanic AYA oncology patients. Huang et al noted that adjusting for neighborhood education level increased the odds for NCIdesignated center use by adult Hispanic patients, 33 suggesting that education level or its associated characteristics influences use. Asians may have cultural barriers similar to those faced by Hispanic patients with regard to immigration status and language, but they do not appear to face the same barriers to the use of SCCs (compared with nonHispanic whites); the reasons for this are not well described and need to be considered in future studies. In previous studies, black patients were more likely to use NCI-designated centers compared with Hispanic and non-Hispanic white patients. 9, 12, 33 However, we observed no significant association with black race/ethnicity and increased SCC use.
It is clear that having public or no insurance is associated with worse outcomes among AYA oncology patients. [36] [37] [38] AYA patients in Los Angeles County with CNS tumors who had public or no health insurance had decreased use of NCI-designated Comprehensive Cancer Centers.
14 In our statewide study, which covered multiple cancer diagnoses and a larger geographic area, this association held true. In addition to a decreased likelihood of receiving all of their care at an SCC, patients with no or public health insurance face multiple challenges, including later stage of diagnosis and the risk of death. 36, 38 Therefore, being less likely to receive treatment at an SCC because of having no or public insurance adds another obstacle to a positive outcome in this vulnerable group's cancer treatment.
Because improved outcomes have been observed among patients who receive care at SCCs, [10] [11] [12] [13] 15 understanding the factors associated with the use of SCCs is an important step toward improving outcomes in this population. Our findings can increase awareness among physicians about the distinct subgroup of patients who are less likely to use SCCs and have them consider referral to SCCs for these patients, when appropriate, thereby possibly improving survival outcomes. Future studies will need to evaluate the factors associated with having no or public insurance so that policy interventions can target these patient populations to either improve their access to private insurance or increase their coverage to allow access to SCCs. In addition, as the Affordable Care Act unfolds, we may witness an improvement in the number of AYA patients covered by private insurance, which may help to alleviate these disparities.
The clinical data used in this study were limited to ICD-9 diagnostic codes and depended on ICD-9 coding accuracy, as with all administrative data sets. In addition, 12% of discharges were not able to be linked to an individual patient. However, we performed regression analysis on the total population using unlinked discharge-level data, and the results were similar. In addition, we were not able to evaluate patients who were treated entirely as outpatients; however, by linking the OSHPD database with other databases, we can begin to address these other diagnoses in future studies. Finally, the population of California may be unique in its ethnic and socioeconomic make-up compared with other parts of the country, which may limit the generalizability of our findings. However, 1 in 10 AYAs reside in California, 39 and the large proportion of Hispanics in California (>35% of the population) provides an important platform allowing for the assessment of health disparities in this growing population. 39 
Conclusion
In this large, comprehensive study of AYA patients with cancer, we identified a distinct subpopulation that is not receiving care at SCCs. Identifying the barriers associated with their decreased use of SCCs is an important and crucial step toward improving outcomes for all AYA patients with cancer. Our findings have implications for clinical care, public policy, and research. The Affordable Care Act reforms should assure that any increases in public payer programs do not inadvertently exacerbate the disparities limiting access to SCCs elucidated by this study. In addition, further research will need to determine how AYA oncology patients end up at SCCs versus community hospitals, which AYA subgroups benefit the most from care at SCCs, and how treatment and supportive care vary at different types of hospitals. We can then determine which interventions, such as educating physicians at nonSCCs, improving referral patterns, and collaboration with partners at non-SCCs or increasing accessibility to SCCs (through improved insurance coverage, transportation, etc), will have the most impact on outcomes in this patient population.
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